A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Clinical trial NCT02955550 · COMPLETED
Trial details
- NCT number
- NCT02955550
- Sponsor
- Celularity Incorporated
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-05
- Primary completion
- 2018-07-10
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.